Merrill reiterates Genzyme at buy

Genzyme Corp. was reiterated at buy by Merrill Lynch analyst Eric Ende after independent investigators reported data from a head-to-head study of Synvisc versus Hyalgan in osteoarthritis of the knee. Synvisc was found to be superior to Hyalgan in pain relief and functional improvement. Merrill expects a boost in Synvisc sales in the second quarter, with an E.U. launch of the product in the second half of the year. Shares of the Cambridge, Mass.-based biotechnology company were down 28 cents, or 0.45%, at $61.47 on volume of 2,067,388 shares versus the three-month running average of 3,086,170 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.